Anti-platelet therapy in coronary heart disease

• Main Authors: O. V. Ermakova, E. V. Kokurina, N. G. Kucheryavaya, E. V. Bochkareva
• Format: Article
• Language: Russian
• Published: «SILICEA-POLIGRAF» LLC 2010-02-01
• Series: Кардиоваскулярная терапия и профилактика
• Subjects: new forms of acetylsalicylic acid; anti-aggregant effect; adverse effects; askolong
• Online Access: https://cardiovascular.elpub.ru/jour/article/view/2023

A new, produced in Russia, form of acetylsalicylic acid (ASA), Askolong, could substantially improve patients’ compliance to long-term anti-aggregant therapy. Oral Askolong (12,5 mg) is absorbed via oral mucosa and does not cause gastrointestinal adverse effects, which are the main reason for treatment discontinuation in patients prescribed most oral ASA forms. Askolong demonstrates anti-aggregant effects similar to those for intestinally absorbed ASC medication ThromboASS. The latter dose of ASA is eight times higher, and gastrointestinal adverse effects are registered in 40% of the patients.